Citadel Advisors
FLGT icon

Citadel Advisors’s Fulgent Genetics FLGT Stock Holding History

Citadel Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
12,000
-6,100
-34% -$132K ﹤0.01% 11461
2025
Q4 		$475K Sell
18,100
-62,600
-78% -$1.62M ﹤0.01% 9150
2025
Q3 		$1.82M Sell
80,700
-42,500
-34% -$875K ﹤0.01% 6263
2025
Q2 		$2.45M Buy
123,200
+68,400
+125% +$1.33M ﹤0.01% 5343
2025
Q1 		$926K Buy
54,800
+16,000
+41% +$273K ﹤0.01% 7134
2024
Q4 		$717K Buy
38,800
+10,100
+35% +$197K ﹤0.01% 7771
2024
Q3 		$624K Buy
28,700
+200
+0.7% +$4.47K ﹤0.01% 7795
2024
Q2 		$559K Sell
28,500
-52,200
-65% -$1.09M ﹤0.01% 7830
2024
Q1 		$1.75M Sell
80,700
-79,600
-50% -$1.98M ﹤0.01% 5787
2023
Q4 		$4.63M Sell
160,300
-42,400
-21% -$1.13M ﹤0.01% 3910
2023
Q3 		$5.42M Buy
202,700
+136,500
+206% +$4.66M ﹤0.01% 3530
2023
Q2 		$2.45M Sell
66,200
-3,700
-5% -$129K ﹤0.01% 4805
2023
Q1 		$2.18M Sell
69,900
-2,600
-4% -$83.7K ﹤0.01% 5191
2022
Q4 		$2.16M Sell
72,500
-61,300
-46% -$2.19M ﹤0.01% 5324
2022
Q3 		$5.1M Sell
133,800
-43,300
-24% -$2.17M ﹤0.01% 3826
2022
Q2 		$9.66M Buy
177,100
+11,600
+7% +$638K ﹤0.01% 2737
2022
Q1 		$10.3M Buy
165,500
+69,200
+72% +$4.56M ﹤0.01% 2895
2021
Q4 		$9.69M Sell
96,300
-12,200
-11% -$1.07M ﹤0.01% 3131
2021
Q3 		$9.76M Sell
108,500
-73,600
-40% -$6.69M ﹤0.01% 3124
2021
Q2 		$16.8M Sell
182,100
-141,800
-44% -$11.3M ﹤0.01% 2310
2021
Q1 		$31.3M Buy
323,900
+12,400
+4% +$1.28M 0.01% 1473
2020
Q4 		$16.2M Buy
311,500
+264,200
+559% +$11M ﹤0.01% 2036
2020
Q3 		$1.89M Buy
+47,300
New +$1.48M ﹤0.01% 4817

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's FLGT Position: Q1 2026 in Review

Citadel Advisors reduced its Fulgent Genetics (FLGT) stake by 78% in Q1 2026, selling an estimated $4.13M and leaving 52,948 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #8055.

Citadel Advisors first reported a position in FLGT in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.2M in Q3 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Citadel Advisors held 52,948 shares of Fulgent Genetics worth $842K as of Q1 2026.
  • Citadel Advisors sold 190,176 Fulgent Genetics shares in Q1 2026, an estimated $4.13M.
  • Fulgent Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8055 holding.
  • Citadel Advisors first reported a position in Fulgent Genetics in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Fulgent Genetics position peaked at $23.2M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.